Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
John F. Seymour(Victorian Comprehensive Cancer Centre), Shuo Ma(Northwestern University), Danielle M. Brander(Duke Medical Center), Michael Y. Choi(University of California, San Diego), Jacqueline C. Barrientos(Hofstra University), Matthew S. Davids(Dana-Farber Cancer Institute), Mary Ann Anderson(Walter and Eliza Hall Institute of Medical Research), Anne Beaven(Duke Medical Center), Steven T. Rosen(City Of Hope National Medical Center), Constantine S. Tam(Victorian Comprehensive Cancer Centre), Betty Prine(AbbVie (United States)), Suresh Agarwal(AbbVie (United States)), Wijith Munasinghe(AbbVie (United States)), Ming Zhu(AbbVie (United States)), Leanne Lash(AbbVie (United States)), Monali Desai(AbbVie (United States)), Elisa Cerri(AbbVie (United States)), Maria Verdugo(AbbVie (United States)), Su Young Kim(AbbVie (United States)), Rod Humerickhouse(AbbVie (United States)), Gary Gordon(AbbVie (United States)), Thomas J. Kipps(University of California, San Diego), Andrew W. Roberts(University of Melbourne)
Cited by 326
Abstract
Related Papers
No related papers found
Powered by citation graph analysis